| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 140 nM (MAGL)[1]
N-Arachidonyl maleimide primarily targets monoacylglycerol lipase (MAGL), the primary enzyme responsible for degrading the endocannabinoid 2-AG. By inhibiting MAGL, it raises 2-AG levels. Some sources also note it may have activity against other targets, such as protein kinase C (PKC), suggesting that its selectivity should be carefully evaluated in experimental systems. |
|---|---|
| ln Vitro |
A potential MAGL inhibitor that can be utilized to control the effects of 2-arachidonyl glycerol (2-AG) is N-arachidonyl maleimide. N-Arachidonyl maleimide raises the brain's natural amounts of 2-AG. At a comparatively modest concentration (IC50, 140 nM), N-arachidonyl maleimide inhibits the breakdown of 2-AG mediated by the cerebellar membrane[1].
In vitro, N-Arachidonyl maleimide functions as a potent inhibitor of monoacylglycerol lipase (MAGL). It is used to control the effects of 2-arachidonyl glycerol (2-AG), an endocannabinoid. By inhibiting MAGL, it prevents the hydrolysis of 2-AG, thereby elevating its concentration in the central nervous system. It is also described as a selective and irreversible inhibitor of protein kinase C (PKC), indicating potential for dual activity. |
| ln Vivo |
2-AG (1, 3, and 10 mg/kg) induces substantial and dose-dependent hypothermia, antinociception, and catalepsy when paired with a 1 mg/kg dosage of N-Arachidonyl maleimide[1].
In vivo, N-Arachidonyl maleimide raises the brain's natural levels of 2-arachidonyl glycerol (2-AG). This effect is central to its use as a pharmacological tool for studying the endocannabinoid system in the central nervous system. It is expected to produce effects similar to other MAGL inhibitors, such as anti-nociception, anti-inflammatory, and anti-anxiety effects in animal models, although specific data is not provided in the source. |
| Enzyme Assay |
To evaluate its MAGL inhibitory activity, a cell-free enzyme assay is performed. Recombinant human MAGL is incubated with varying concentrations of NAM in a reaction buffer. The reaction is initiated by adding the substrate, 2-oleoylglycerol or 2-AG. The hydrolysis product (fatty acid) is measured to determine the IC50. For PKC inhibition, a standard kinase assay using purified PKC and a peptide substrate can be used.
|
| Cell Assay |
For cell-based assays, the compound can be used to treat neuroblastoma cell lines (e.g., Neuro-2a) or primary cortical neurons. Cells are treated with NAM (e.g., 0.1-10 uM) for 1-4 hours. Cell lysates are then collected, and residual MAGL activity is measured. Alternatively, 2-AG levels in the cell lysates are directly measured by LC-MS/MS, where an increase in 2-AG levels indicates successful target inhibition.
|
| Animal Protocol |
A typical in vivo protocol for demonstrating the effect of NAM on brain 2-AG levels involves adult male mice. N-Arachidonyl maleimide is formulated in a vehicle such as 5% DMSO, 5% Tween-80, and 90% saline. It is administered via intraperitoneal injection at doses ranging from 1-20 mg/kg. After a set period (e.g., 1-4 hours), animals are euthanized, and their brains are rapidly dissected. Brain tissue is homogenized, and lipids are extracted for the quantification of 2-arachidonoylglycerol (2-AG) and other endocannabinoids by LC-MS/MS. A significant increase in 2-AG compared to vehicle-treated controls confirms target engagement.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for N-Arachidonyl maleimide is limited. The compound has a molecular weight of 369.55 g/mol. Its lipophilic structure suggests that it is likely to be well absorbed and cross the blood-brain barrier. For any in vivo study, pilot PK studies are essential to determine key parameters like half-life, Cmax, and brain penetration in the specific animal model.
|
| Toxicity/Toxicokinetics |
Published toxicology data for N-Arachidonyl maleimide is limited. In research settings, cell viability should be assessed in parallel with efficacy assays to determine non-toxic concentrations. Based on its mechanism as a MAGL inhibitor, it is not expected to be directly cytotoxic. The compound should be stored as a solution or powder at -80degC for long-term stability, as recommended by suppliers. Standard laboratory safety precautions apply.
|
| References |
|
| Additional Infomation |
N-Arachidonyl maleimide is a research-grade compound and is not approved for clinical use. It is a chemical tool for studying the endocannabinoid system. Its described activity against both MAGL and PKC suggests it is a multi-target compound, and results should be interpreted with caution. It is typically stored at -80degC, protected from light. For research use only.
|
| Molecular Formula |
C24H35NO2
|
|---|---|
| Molecular Weight |
369.54
|
| Exact Mass |
369.266
|
| CAS # |
876305-42-9
|
| PubChem CID |
25021164
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
492.9±34.0 °C at 760 mmHg
|
| Flash Point |
185.2±18.0 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.524
|
| LogP |
7.89
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
27
|
| Complexity |
549
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCN1C(=O)C=CC1=O
|
| InChi Key |
GZNZRHSGGQUYAP-DOFZRALJSA-N
|
| InChi Code |
InChI=1S/C24H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-25-23(26)20-21-24(25)27/h6-7,9-10,12-13,15-16,20-21H,2-5,8,11,14,17-19,22H2,1H3/b7-6-,10-9-,13-12-,16-15-
|
| Chemical Name |
1-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenyl]pyrrole-2,5-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (270.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.77 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7061 mL | 13.5303 mL | 27.0607 mL | |
| 5 mM | 0.5412 mL | 2.7061 mL | 5.4121 mL | |
| 10 mM | 0.2706 mL | 1.3530 mL | 2.7061 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
